RxDoctor Payments Data

Edwin Lee, MD

Interventional Cardiology · Los Angeles, CANPI 1629244918

Payments from drug & device makers

$27,158in general payments, 2019–2025

Across 552 payments — averaging $49.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11K
  • Abbott$6K
  • Bayer$1K
  • Novartis$1K
  • AstraZeneca$982
  • Actelion Pharmaceuticals US, Inc.$791
  • plus $6K from 27 others

What the payments were for

  • Speaking & faculty fees$8,25030%
  • Food & beverage$18,51368%
  • Education$3941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,158 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$479,567
Medicare patients
522
Services billed
3,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan36$435,741
EntrestoSacubitril/Valsartan229$239,053
EliquisApixaban129$131,974
Repatha SureclickEvolocumab104$72,440
KerendiaFinerenone49$63,466
JardianceEmpagliflozin52$57,602
FarxigaDapagliflozin Propanediol51$44,889
VerquvoVericiguat27$28,541
OzempicSemaglutide18$25,160
BrilintaTicagrelor27$23,053
TrulicityDulaglutide18$19,201
Praluent PenAlirocumab19$9,336
InpefaSotagliflozin11$6,270
Amiodarone Hcl34$2,903
Digoxin24$2,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$791$435,74136 claims
NovartisEntresto$1,117$239,053229 claims
PfizerEliquis$433$131,974129 claims
AstraZenecaFarxiga, Brilinta$982$67,94178 claims
BayerKerendia$1,443$63,46649 claims
Boehringer IngelheimJardiance$497$57,60252 claims
MerckVerquvo$570$28,54127 claims
Novo NordiskOzempic$182$25,16018 claims
Lilly USA, LLCTrulicity$87$19,20118 claims
Lexicon Pharmaceuticals, Inc.Inpefa$216$6,27011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →